MondayNightIBD

November 2026 - May 2027

This activity is jointly provided by Global Education Group (Global) and Bonum CE in partnership with MondayNightIBD.

Supported by educational grants from Johnson & Johnson, and Takeda Pharmaceuticals U.S.A., Inc.

Program Overview

The management of inflammatory bowel disease (IBD) is an ever-evolving field. The past decade of developments has led to improved understanding of the disease, management focus beyond symptom control, emphasis on preventing disease progression while avoiding bowel damage and disability, new therapeutic options, and improved treatment algorithms. Additionally, with the rapid and ongoing expansion of IBD therapies (including several characterized by novel mechanisms of action) clinicians are faced with the task of ensuring that their knowledge of the full spectrum of available therapies is both accurate and up to date all the while recognizing nuance in guidelines, patient preferences in a constantly evolving field.

MondayNightIBD, is a serialized CME-certified program that addresses many of these complex clinical questions through our bi-weekly, X/Twitter-based Clinical Conversations, #PatientExperience Conversations, #Back2Basics Tweetorials, and wrap-up Algorithms.

Program Chair

Aline Charabaty, MD, FACG, AGAF (moderator)
Professor of Medicine
Director of the Inflammatory Bowel Disease Program
Division of Gastroenterology and Hepatology
University of Maryland Medical Center
Baltimore, MD

Schedule

1	Event Date	Topic

2	Nov 16, 2026	Webinar: Clinical Trials in IBD
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Target Audience

Gastroenterologists (GIs), GIs in training, surgeons, subspecialists such as dieticians and psychologists, nurse practitioners (NPs), physician assistants (PAs), nurses, and other healthcare team members involved in or interested in the care of patients with IBD.

Learning Objectives

After completing this activity series, learners should be better able to:
1. Assess objective measures of disease activity, including fecal calprotectin, endoscopy, histology, and intestinal ultrasound, to prevent disease progression, bowel damage, and disability in patients with IBD.
2. Identify guideline-directed, evidence-based approaches for the management of patients with moderate-to-severe IBD
3. Assess the clinical safety and efficacy data for recently approved and emerging therapies across mechanism classes
4. Evaluate positioning and sequencing of IBD therapeutics
5. Evaluate evolving safety considerations for advanced IBD therapies, including cardiovascular and thromboembolic risk profiles for JAK inhibitors in IBD populations
6. Evaluate the role of novel agents, inclusive of biosimilar and originator comparative data, to achieve an individualized, patient-centered approach to IBD management
7. Discuss situations of disparate and reduced access impacting patients with IBD from minoritized and marginalized populations
8. Review communication challenges between clinicians and patients with IBD, including bowel urgency and other patient-prioritized symptoms

Disclosures of Relevant Financial Relationships

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are appropriately identified as relevant by Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners.

The faculty have the following relevant financial relationships with ineligible companies:

Aline Charabaty, MD, (chair)
Consulting: AbbVie, Janssen, Eli Lilly, Pfizer, Sanofi
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
Bonum CE staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Certification

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Global Education Group and BonumCE. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit & Fee Information

In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 100% on the post-survey, complete the evaluation and application for credit form.

Completion of the above referenced materials must be submitted to the program organizers within one year of the case conversation launch date. Requests for credit made more than 12 months following each activity posting date will not be eligible for a certificate. The organizers encourage learners, particularly those with regular participation in MondayNightIBD activities, to complete post-surveys, evaluation & credit claim forms on a weekly or monthly basis if at all possible.

There is no fee to participate in this program.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global, collaborators, and faculty on this program do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

All Bonum CE digital activities require the following hardware/software to view and participate:

Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)
PowerPoint and/or a PDF viewer may be required on some activities

We recommend a minimum of:

128MB RAM
Processor speed of 500MHz or higher
800x600 color monitor
Video or graphics card
Sound card and speakers

To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.

Contact Information

For information about the joint accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Estimated time to complete each activity: 60 minutes